Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd is positioned for growth, driven by positive developments in its photocurable dermal filler and breast-implant programs, potentially enhancing market outlook and cash flow. The company's newly operational U.S.-based logistics center is expected to boost sales for its BioInk and rhCollagen products, particularly as adoption increases among research institutions and tissue-engineering clients. Additionally, the ongoing partnership with AbbVie, which includes exclusive licensing for developing dermal fillers, combined with advancements in CollPlant's product pipeline, underpins a favorable financial trajectory for the company.

Bears say

CollPlant Biotechnologies Ltd has experienced a negative market reaction following a modest capital raise, indicating a loss of investor confidence amid challenging capital market conditions. The pricing at $1.25 per share suggests ongoing pressure on the company's equity and highlights limited options for capital formation. Additionally, the company has adjusted its forecasts by reducing expectations for key products, including Dermal Fillers and BioInk, while also removing Breast Implants from financial models, emphasizing the uncertainty and early-stage developments within its product offerings.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.